ReShape Lifesciences Inc. Faces Potential Nasdaq Delisting After Failing to Meet Equity Requirement

Reuters

2025/05/31

ReShape Lifesciences Inc. Faces Potential Nasdaq Delisting After Failing to Meet Equity Requirement

ReShape Lifesciences Inc. has announced that it received a written notice from the Nasdaq Stock Market's Listing Qualifications Department, indicating the company's securities are set for delisting. This follows an earlier notification from Nasdaq in November 2024, stating that ReShape Lifesciences did not meet the minimum $2,500,000 stockholders' equity requirement for continued listing under Nasdaq Listing Rule 5550(b). While the company was granted an extension until May 27, 2025, to comply, it failed to meet the necessary terms. Unless ReShape Lifesciences appeals this decision by June 4, 2025, trading of its common stock will be suspended on June 6, 2025, and a Form 25-NSE will be filed to remove its securities from listing and registration on Nasdaq. The company plans to appeal the decision, but there is no assurance that the appeal will be successful or that it will maintain compliance with other Nasdaq Listing Rules.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ReShape Lifesciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-054856), on May 30, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2539270913"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539270913\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539270913?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-31 04:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539270913","market":"nz","top_or_hot":-1,"title":"ReShape Lifesciences Inc. Faces Potential Nasdaq Delisting After Failing to Meet Equity Requirement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ReShape Lifesciences Inc. Faces Potential Nasdaq Delisting After Failing to Meet Equity Requirement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ReShape Lifesciences Inc. has announced that it received a written notice from the Nasdaq Stock Market's Listing Qualifications Department, indicating the company's securities are set for delisting. This follows an earlier notification from Nasdaq in November 2024, stating that ReShape Lifesciences did not meet the minimum $2,500,000 stockholders' equity requirement for continued listing under Nasdaq Listing Rule 5550(b). While the company was granted an extension until May 27, 2025, to comply, it failed to meet the necessary terms. Unless ReShape Lifesciences appeals this decision by June 4, 2025, trading of its common stock will be suspended on June 6, 2025, and a Form 25-NSE will be filed to remove its securities from listing and registration on Nasdaq. The company plans to appeal the decision, but there is no assurance that the appeal will be successful or that it will maintain compliance with other Nasdaq Listing Rules.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ReShape Lifesciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-054856), on May 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ReShape Lifesciences Inc. Faces Potential Nasdaq Delisting After Failing to Meet Equity Requirement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReShape Lifesciences Inc. Faces Potential Nasdaq Delisting After Failing to Meet Equity Requirement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-31 04:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ReShape Lifesciences Inc. Faces Potential Nasdaq Delisting After Failing to Meet Equity Requirement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ReShape Lifesciences Inc. has announced that it received a written notice from the Nasdaq Stock Market's Listing Qualifications Department, indicating the company's securities are set for delisting. This follows an earlier notification from Nasdaq in November 2024, stating that ReShape Lifesciences did not meet the minimum $2,500,000 stockholders' equity requirement for continued listing under Nasdaq Listing Rule 5550(b). While the company was granted an extension until May 27, 2025, to comply, it failed to meet the necessary terms. Unless ReShape Lifesciences appeals this decision by June 4, 2025, trading of its common stock will be suspended on June 6, 2025, and a Form 25-NSE will be filed to remove its securities from listing and registration on Nasdaq. The company plans to appeal the decision, but there is no assurance that the appeal will be successful or that it will maintain compliance with other Nasdaq Listing Rules.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ReShape Lifesciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-054856), on May 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDLb3bMMn:1","article_id":"2539270913","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539270913","pubTimestamp":1748635470,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ReShape Lifesciences Inc. has announced that it received a written notice from the Nasdaq Stock Market's Listing Qualifications Department, indicating the company's securities are set for delisting. This follows an earlier notification from Nasdaq in November 2024, stating that ReShape Lifesciences did not meet the minimum $2,500,000 stockholders' equity requirement for continued listing under Nasdaq Listing Rule 5550. While the company was granted an extension until May 27, 2025, to comply, it failed to meet the necessary terms. Unless ReShape Lifesciences appeals this decision by June 4, 2025, trading of its common stock will be suspended on June 6, 2025, and a Form 25-NSE will be filed to remove its securities from listing and registration on Nasdaq. The company plans to appeal the decision, but there is no assurance that the appeal will be successful or that it will maintain compliance with other Nasdaq Listing Rules.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备"},"translate_title":"重塑生命科学公司因未能满足股权要求而可能面临纳斯达克退市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RSLS":0.9},"content_text":"ReShape Lifesciences Inc. Faces Potential Nasdaq Delisting After Failing to Meet Equity Requirement\n    \n\n        ReShape Lifesciences Inc. has announced that it received a written notice from the Nasdaq Stock Market's Listing Qualifications Department, indicating the company's securities are set for delisting. This follows an earlier notification from Nasdaq in November 2024, stating that ReShape Lifesciences did not meet the minimum $2,500,000 stockholders' equity requirement for continued listing under Nasdaq Listing Rule 5550(b). While the company was granted an extension until May 27, 2025, to comply, it failed to meet the necessary terms. Unless ReShape Lifesciences appeals this decision by June 4, 2025, trading of its common stock will be suspended on June 6, 2025, and a Form 25-NSE will be filed to remove its securities from listing and registration on Nasdaq. The company plans to appeal the decision, but there is no assurance that the appeal will be successful or that it will maintain compliance with other Nasdaq Listing Rules.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ReShape Lifesciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-054856), on May 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}